Abbott Laboratories entered into an agreement with Spain-based global biotech company mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women’s health, and respiratory diseases in emerging markets.

The first molecules are expected to launch in 2025, while others are subject to the completion of clinical development and registration. Abbott will register and commercialize the biosimilars in key emerging countries in Latin America, Southeast Asia, the Middle East, and Africa.

mAbxience will manufacture the biosimilars at its GMP approved facilities in Spain and Argentina. In addition, mAbxience will be responsible for achieving the clinical milestones for some of the molecules still undergoing development.

The collaboration broadens Abbott’s medicines offering in emerging countries and expands an existing agreement with mAbxience, initiated in Latin America 2018.

“The expanded collaboration with mAbxience will complement our existing branded generic medicines portfolio with state-of-the-art biosimilars,” said Daniel Salvadori, executive vice president and group president, established pharmaceuticals and nutritional products, Abbott. “With our large footprint in emerging countries and our commitment to put access and affordability at the center of what we do, this strategic collaboration will help more people in more places have access to affordable biosimilar medicines.” 

“Collaborating with Abbott’s medicines business is a key strategic step to help bring our biosimilars into the hands of more people who need them,” said Emmanuelle Lepine, chief executive officer, mAbxience. “Abbott shares a common vision of making high-quality medicines available so that healthcare systems can have cost-effective treatment options, with an opportunity for more people around the world to get healthier. This new agreement supports our strategy of becoming a leading global player within the biosimilar space.”